“It has been an enriching experience being part of BrainCool’s development over the past ten years. After the successful rights issue in May and with three new Board Directors joining in June, BrainCool has entered a new phase. I think this is a suitable time to hand over the responsibility to the new Board as it now has the full grasp of the company. I see continued great potential in the company´s future, which I will closely follow in my role as an investor,” comments Hans Henriksson, BrainCool’s outgoing Chairman of the Board.

Jens Lindberg was elected as a new Board Director of BrainCool at the annual general meeting in June 2024. He has 25 years of international experience in life science and a proven track record in developing and commercializing innovative products. He is currently CEO of Medivir AB, with a previous background as interim CEO and VP of Global Commercial Operations at Sedana Medical AB, as well as from several senior positions at Astra Zeneca plc.

“Since joining the Board of BrainCool in June, I have been able to acquire in-depth knowledge of the company. I am impressed with the level of innovation in the product portfolio and the great engagement of the entire team. We have a solid foundation to take the next step in establishing BrainCool™ System as the preferred option in surface cooling and bringing RhinoChill® to a commercialization phase, all with the aim of improving the lives of patients with stroke and cardiac arrest. In my new role as Chairman of the Board, I look forward to working closely with our CEO, Jon Berg, and the team to ensure continued success. I would also like to take the opportunity to thank Hans Henriksson for his great contributions to BrainCool over the company’s first 10 years,” said Jens Lindberg, BrainCool’s incoming Chairman of the Board.

Jens Lindberg (b. 1971) is considered independent in relation to the company, its management and the company's major shareholders.